Роль афлиберцепта в лечении метастатического колоректального рака


А.А. Мещеряков

ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва
Афлиберцепт – один из последних таргетных препаратов, доказавших эффективность в лечении больных метастатическим колоректальным раком. Препарат зарегистрирован для второй линии лечения в комбинации со схемой FOLFIRI после применения оксалиплатин-содержащих режимов химиотерапии. В обзоре представлены общие сведения об опухолевом ангиогенезе, механизме действия афлиберцепта, результатах применения антиангиогенной терапии в первой и второй линиях лекарственного лечения диссеминированного колоректального рака.

Литература



  1. Hicklin D.J., Ellis L. M. Role of the vascular endothelial growth factor pathway in the tumor growth and angiogenesis. J. Clin. Oncol. 2005;23:1011–27.

  2. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp. Cell Res. 2006;312:549–60.

  3. Ferrara N. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 2004;3:391–400.

  4. Hurwitz H., Fehrenbacher L., Novotny W. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004;350:2335–42.

  5. Schmoll H., Van Cutsem E., Stein A. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol. 2012;23:2479–16.

  6. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J. Clin. Oncol. 2007;25:4779–86.

  7. Saltz L.B., Clarke S., Diaz-Rubio E. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 2008;26:2013–19.

  8. Tebbutt N.C., Wilson K., Gebski V.J. et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J. Clin. Oncol. 2010;28:3191–98.

  9. Kabbinavar F.F., Schulz J., McCleod M. et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J. Clin. Oncol. 2005;23:3697–705.

  10. Heinemann V., von Weikersthal L.F., Decker T. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. doi: 10.1016/S1470-2045(14)70330-4. Epub 2014 Jul 31.

  11. Venook A.P., Niedzwiecki D., Lenz Heinz-Josef et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J. Clin. Oncol. 2014;32: (suppl 5s; abstr LBA3)

  12. Bennouna J., Sastre J., Arnold D. et al., on behalf of the ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomized phase 3 trial. www.thelancet.com/oncology Published online November 16, 2012, http://dx.doi.org/10.1016/S1470-2045(12)70477-1.

  13. Van Cutsem E., Tabernero J., Lakomy R. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Published ahead of print on September 17, 2012, http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.42.8201

  14. Chau I., Joulain F., Iqbal S. U. et al. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer. 2014;14:605. doi: 10.1186/1471-2407-14-605.


Об авторах / Для корреспонденции


А.А. Мещеряков – к.м.н., с.н.с., ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» РАМН, Москва; e-mail: a_meshcheryakov@mail.ru


Похожие статьи


Бионика Медиа